Current challenges in chronic graft-versus-host disease.

[1]  B. Djulbegovic,et al.  Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  B. Storer,et al.  Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. , 2009, Blood.

[3]  J. Fay,et al.  Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. , 2009, Blood.

[4]  J. Ritz,et al.  Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. , 2009, Blood.

[5]  S. Lee,et al.  Feasibility of NIH consensus criteria for chronic graft-versus-host disease , 2009, Leukemia.

[6]  J. Witte,et al.  New classification of chronic GVHD: added clarity from the consensus diagnoses , 2009, Bone Marrow Transplantation.

[7]  G. Vogelsang,et al.  Chronic graft versus host disease , 2004, British journal of haematology.

[8]  M. MacMillan,et al.  New Classification of Chronic Graft Versus Host Disease: Added Clarity from the Consensus Diagnoses. , 2007 .

[9]  J. Ritz,et al.  High Levels of B-Cell Activating Factor in Patients with Active Chronic Graft-Versus-Host Disease , 2007, Clinical Cancer Research.

[10]  Heidi Chen,et al.  Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  J. Ritz,et al.  IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. , 2006, Blood.

[12]  J. Ritz,et al.  Rituximab for steroid-refractory chronic graft-versus-host disease. , 2006, Blood.

[13]  S. Hirschfeld,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  P. Lachenbruch,et al.  Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  J. Ritz,et al.  Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. , 2005, Blood.

[16]  Catherine J. Wu,et al.  Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. , 2004, Blood.

[17]  M. Turner,et al.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  J. Ritz,et al.  Minor Histocompatibility Antigen DBY Elicits a Coordinated B and T Cell Response after Allogeneic Stem Cell Transplantation , 2004, The Journal of experimental medicine.

[19]  M. Flowers,et al.  Diagnosis and clinical management of chronic graft-versus-host disease , 2004, International journal of hematology.

[20]  J. Ritz,et al.  Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. , 2004, Blood.

[21]  F. Appelbaum,et al.  Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. , 2004, Blood.

[22]  M. Maris,et al.  Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. , 2003, Blood.

[23]  E. Cook,et al.  Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[24]  H. Deeg,et al.  Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. , 2002, Blood.

[25]  S. Davies,et al.  Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[26]  H. Deeg,et al.  Thalidomide for treatment of patients with chronic graft-versus-host disease. , 2000, Blood.

[27]  Jean E. Sanders,et al.  Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. , 1988, Blood.

[28]  H. Deeg,et al.  Prednisone and Azathioprine Compared With Prednisone and Placebo for Treatment of Chronic Graft-v-Host Disease : Prognostic Influence of Prolonged Thrombocytopenia After Allogeneic Marrow Transplantation , 2005 .

[29]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.